Data from Enhanced Apoptosis and Tumor Growth Suppression Elicited by Combination of MEK (Selumetinib) and mTOR Kinase Inhibitors (AZD8055)

Sarah V. Holt(Pharma Nord (United Kingdom)), Paul D. Smith(Duquesne University), Christine M. Chresta(AstraZeneca (United Kingdom)), Sarah E. Fenton, Sarah Runswick(Allgemeine Gewerbeschule Basel), Sylvie M. Guichard(Novo Nordisk (United Kingdom)), Robert W. Wilkinson(Immunocore (United Kingdom)), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Jingchuan Zhang(Shanghai Innovative Research Center of Traditional Chinese Medicine), Yi Gu(Beijing Information Science & Technology University), Barry R. Davies(Immodulon Therapeutics (United Kingdom)), Armelle Logié(Sorbonne Université), Denis Alférez(AstraZeneca (United Kingdom))
Unknown
March 30, 2023
10.1158/0008-5472.c.6503583.v1
Cited by 0

Related Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k